Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus (Record no. 20833)

MARC details
000 -LEADER
fixed length control field a
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240403102036.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 240403b xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency AIKTC-KRRC
Transcribing agency AIKTC-KRRC
100 ## - MAIN ENTRY--PERSONAL NAME
9 (RLIN) 23153
Author Bose, Debdipta
245 ## - TITLE STATEMENT
Title Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus
Remainder of title :A meta-analysis of landmark renal and cardiovascular outcome trials
250 ## - EDITION STATEMENT
Volume, Issue number Vol.55(2), Mar-Apr
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Mumbai
Name of publisher, distributor, etc. Wolter Kluwer
Year 2023
300 ## - PHYSICAL DESCRIPTION
Pagination 119-127p.
520 ## - SUMMARY, ETC.
Summary, etc. Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are recommended as the next step therapy for the management of diabetes mellitus. The large clinical trials of SGLT2is demonstrated benefits on various renal endpoints. We conducted this meta-analysis of large trials on cardiovascular and renal safety trials to explore the renoprotective effect of this group of drugs. PubMed, Cochrane CENTRAL, and EMBASE databases were searched with specific keywords till January 19, 2021. Randomized trials of SGLT2is that evaluated the cardiovascular or renal composite outcome as a primary outcome measure were eligible. Random-effects model was used to calculate the overall risk ratios. The search yielded 716 studies and 10 studies were included. The SGLT2is reduced the risk of composite renal outcome (risk ratio [RR] = 0.64, 95% confidence interval [CI] = 0.58–0.72), decline in estimated glomerular filtration rate (eGFR) (RR = 0.62, 95% CI = 0.50–0.77), doubling of serum creatinine (RR = 0.67, 95% CI = 0.56–0.81), dialysis or renal replacement therapy (RR = 0.71, 95% CI = 0.59–0.86), sustained eGFR of <15 ml per min per 1.73 m2 for at least 30 days or more (RR = 0.66, 95% CI = 0.55–0.81), end-stage renal disease (RR = 0.70, 95% CI = 0.56–0.87), and acute kidney injury (RR = 0.79, 95% CI = 0.71–0.89). This analysis establishes the renoprotective effect of SGLT2is. This benefit is noted in patients who had eGFR of more or <60 ml per min per 1.73 m2. This benefit was uniform across all the SGLT2 inhibitors except ertugliflozin and sotagliflozin.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 4774
Topical term or geographic name entry element PHARMACOLOGY
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 23154
Co-Author Maurya, Miteshkumar
773 0# - HOST ITEM ENTRY
Title Indian Journal of Pharmacology
International Standard Serial Number 0253-7613
Place, publisher, and date of publication Andheri - Mumbai Wolters Kluwer India Private Limited
856 ## - ELECTRONIC LOCATION AND ACCESS
URL https://journals.lww.com/iphr/fulltext/2023/55020/impact_of_sodium_glucose_co_transporter_2.6.aspx
Link text Click here
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Articles Abstract Database
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Barcode Date last seen Price effective from Koha item type
    Dewey Decimal Classification     School of Pharmacy School of Pharmacy Archieval Section 03/04/2024   2024-0391 03/04/2024 03/04/2024 Articles Abstract Database
Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.